Will disease heterogeneity help define treatment paradigms for gastroesophageal adenocarcinoma? A global perspective.
Cancers of the upper gastrointestinal (GI) tract form a heterogeneous group of diseases for which treatment paradigms for localized disease continue to emerge. Recently, several phase III studies in esophagus and gastric cancer that have attempted to define new standards of care have been reported. However, controversy still persists and treatment algorithms often depend on individual preference, patient referral patterns, and treatment biases. In the current era of improving quality control and standardization of care, such variations in practice present a substantial challenge for both patients and physicians. In this article, I will highlight differences in disease biology for upper GI diseases, and in particular, gastric cancer.